Magnesium Supplementation to Prevent Bone Loss
Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypothesize that magnesium supplementation will have a beneficial effect on calcium regulating hormones and markers of bone turnover.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Magnesium Supplementation to Prevent Bone Loss|
- Biomarkers bone turnover (P1NP and CTX)
- Calcium regulating hormones (PTH and 1,25 dihydroxyvitamin D)
- Change in BMD at the spine, femoral neck and total hip by DXA
- Change in RBC magnesium
|Study Start Date:||July 2002|
|Estimated Study Completion Date:||September 2006|
This is a 12 month randomized, double-blind, placebo-controlled study of magnesium supplementation. Our hypothesis was that magnesium supplementation would decrease bone turnover markers and alter calcium-regulating hormones: parathyroid hormone and 1, 25 dihydroxyvitamin D.
Male and female adults over 55 without with a T-score at the hip above -2 are randomized to magnesium 250 mg BID or identical placebo BID. At baseline, all participants had a bone mineral density (BMD) by DXA scan at the hip and spine, blood biomarkers of bone resorption and formation, and calcium regulating hormones. Participants were followed for 12 months, with repeat measurement of calcium regulating hormones and bone turnover markers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346658
|United States, Tennessee|
|University of Tennessee Health Sciences Center|
|Memphis, Tennessee, United States, 38163|
|Principal Investigator:||Kathryn M Ryder, MD, MS||University of Tennessee Health Sciences Center|